GlaxoSmithKline plc (GSK) Given a GBX 1,834 Price Target by Sanford C. Bernstein Analysts
GlaxoSmithKline plc (LON:GSK) received a GBX 1,834 ($22.35) target price from Sanford C. Bernstein in a note issued to investors on Wednesday. The firm currently has a a “neutral” rating on the stock. Sanford C. Bernstein’s price target suggests a potential upside of 10.02% from the stock’s previous close.
GSK has been the topic of a number of other reports. Shore Capital reissued a “hold” rating on shares of GlaxoSmithKline plc in a report on Wednesday, July 27th. Deutsche Bank AG reissued a “hold” rating and set a GBX 1,700 ($20.72) target price on shares of GlaxoSmithKline plc in a report on Thursday, July 28th. Jefferies Group raised shares of GlaxoSmithKline plc to a “buy” rating and boosted their target price for the stock from GBX 1,650 ($20.11) to GBX 2,000 ($24.38) in a report on Thursday, July 14th. BNP Paribas reissued a “neutral” rating and set a GBX 1,430 ($17.43) target price on shares of GlaxoSmithKline plc in a report on Sunday, July 3rd. Finally, Independent Research GmbH set a GBX 1,800 ($21.94) price target on shares of GlaxoSmithKline plc and gave the stock a “neutral” rating in a research report on Thursday, August 4th. Three equities research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and eight have given a buy rating to the company’s stock. GlaxoSmithKline plc has an average rating of “Hold” and an average target price of GBX 1,680.71 ($20.48).
GlaxoSmithKline plc (LON:GSK) traded down 0.33% during midday trading on Wednesday, reaching GBX 1661.50. 2,331,722 shares of the company’s stock traded hands. GlaxoSmithKline plc has a 1-year low of GBX 1,277.25 and a 1-year high of GBX 1,745.56. The stock’s 50 day moving average price is GBX 1,651.49 and its 200 day moving average price is GBX 1,567.94. The firm’s market cap is GBX 80.77 billion.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/19/glaxosmithkline-plc-gsk-given-a-gbx-1834-price-target-by-sanford-c-bernstein-analysts.html
The company also recently declared a dividend, which was paid on Thursday, October 13th. Stockholders of record on Thursday, August 11th were issued a GBX 19 ($0.23) dividend. This represents a dividend yield of 1.12%. The ex-dividend date was Thursday, August 11th.
In other news, insider Slaoui,Moncef purchased 28 shares of the stock in a transaction dated Friday, August 12th. The shares were purchased at an average cost of GBX 2,208 ($26.91) per share, with a total value of £618.24 ($753.49). Also, insider Witty,Sir Andrew P sold 10,000 shares of the stock in a transaction dated Wednesday, July 27th. The stock was sold at an average price of GBX 1,693 ($20.63), for a total transaction of £169,300 ($206,337.60).
About GlaxoSmithKline plc
GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.